Stay up-to-date with the latest developments in securities law through access to both news and all statutes and regulations. Find relevant corporate filings through a searchable EDGAR database. And...
Aug. 26 — Auspex Pharmaceuticals Inc. shareholders can't proceed with a would-be class action challenging the company's $3.5 billion merger with Teva Pharmaceutical Industries Ltd., the Delaware Chancery Court ruled Aug. 25 ( Larkin v. Shah, 2016 BL 277097, Del. Ch., No. 10918-VCS, 8/25/16 ).
The shareholder plaintiffs alleged that venture capital firms that owned Auspex stock and directors that had ties to the firms pushed through the all-cash transaction at the expense of other stockholders.
Vice Chancellor Joseph R. Slights III dismissed the claims, finding that the case didn't involve a controlling shareholder that tainted the deal. He found that even if a controller had existed, the plaintiffs couldn't show the venture capital firms had a conflict of interest.
The court also concluded that absent a controlling stockholder, the deal must be reviewed under the deferential business judgment rule, citing two recent Delaware Supreme Court rulings— Corwin v. KKR Fin. Holdings LLC, 2015 BL 323544 (193 SLD, 10/6/15) and Singh v. Attenborough, 2016 BL 145197 .
This ruling marks the second time in as many days that the chancery court has applied Corwin and Singh, which make it harder for plaintiffs to succeed in certain merger challenges. The court applied the two cases Aug. 24 in dismissing a shareholder lawsuit over C&J Energy Services Inc.'s $2.86 billion merger with a unit of Nabors Industries Ltd.
Corwin and Singh hold that where a transaction is approved by a fully informed, uncoerced stockholder vote, the business judgment standard of review—which defers to corporate decision-making—must be applied unless challenged on the basis of waste.
Teva, one of the largest generic drug producers in the world, in 2015 acquired Auspex in a two-step merger. Under the transaction, a buyer purchases a majority of a public company's shares through a tender offer, then completes the back-end of the merger by acquiring the remaining shares.
Because more than half of Auspex's outstanding shares were tendered to Teva, the merger occurred under Delaware's two-step merger statute—General Corporation Law Section 251(h)—without a stockholder vote.
Slights applied a July chancery court ruling— In re Volcano Corp. Stockholder Litig.—that provided that stockholders' acceptance of a tender offer under Section 251(h) has the same cleansing effect as a stockholder vote in favor of the transaction (128 SLD, 7/5/16).
To contact the reporter on this story: Michael Greene in Washington at email@example.com
To contact the editor responsible for this story: Yin Wilczek at firstname.lastname@example.org
The opinion is available at http://src.bna.com/h5a.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)